Bacterial vaginosis and vulvovaginal candidiasis are bacterial infections widely spread among women in childbearing age. These infections are associated with altered or disturbed vaginal microbiota, in a condition defined as vaginal dysbiosis. Restoration of the lactobacilli flora seems a promising strategy for the treatment of these pathologies. The efficacy and safety of a new vaginal composition, containing three Lactobacillus strains selected for their activity against urogenital pathogens, was assessed in a pilot clinical trial for the treatment of bacterial vaginosis and vaginal candidiasis. The study involved women with a diagnosis of bacterial vaginosis (30) or vulvovaginal candidiasis (24).
Vaginal capsules, containing the three Lactobacillus strains, were administered following one application per day for ten consecutive days. Patients received gynecological examinations before and after treatment, with objective examination, assessment of clinical symptoms severity, and vaginal wet mount microscopy. The treatment showed complete resolution in 60% of bacterial vaginosis cases and around 40% in vulvovaginal candidiasis cases. Further analyzing the subgroup characterized by recurrent vaginal candidiasis, the success rate was significantly higher than in the acute cases, showing a stronger effect of the product against persistent and chronic conditions. The product showed a resolution of the vaginal dysbiosis through vaginal wet mount examination, and no adverse effects were reported. In conclusion, the presented clinical data support the use of the Lactobacillus vaginal composition for the treatment of bacterial vaginosis and vulvovaginal candidiasis